150 related articles for article (PubMed ID: 15081215)
1. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats.
Bosquillon C; Préat V; Vanbever R
J Control Release; 2004 Apr; 96(2):233-44. PubMed ID: 15081215
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats.
Codrons V; Vanderbist F; Verbeeck RK; Arras M; Lison D; Préat V; Vanbever R
J Pharm Sci; 2003 May; 92(5):938-50. PubMed ID: 12712413
[TBL] [Abstract][Full Text] [Related]
4. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
5. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
7. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
8. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
Cruz L; Fattal E; Tasso L; Freitas GC; Carregaro AB; Guterres SS; Pohlmann AR; Tsapis N
J Control Release; 2011 Jun; 152(3):370-5. PubMed ID: 21396412
[TBL] [Abstract][Full Text] [Related]
9. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
Bosquillon C; Lombry C; Préat V; Vanbever R
J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
[TBL] [Abstract][Full Text] [Related]
10. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
11. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
12. Insulin-micro- and nanoparticles for pulmonary delivery.
Klingler C; Müller BW; Steckel H
Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
[TBL] [Abstract][Full Text] [Related]
13. Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7- micro m fluorescein aerosols.
Sakagami M; Kinoshita W; Sakon K; Makino Y
Arch Toxicol; 2003 Jun; 77(6):321-9. PubMed ID: 12799771
[TBL] [Abstract][Full Text] [Related]
14. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium.
Gervelas C; Serandour AL; Geiger S; Grillon G; Fritsch P; Taulelle C; Le Gall B; Benech H; Deverre JR; Fattal E; Tsapis N
J Control Release; 2007 Mar; 118(1):78-86. PubMed ID: 17241685
[TBL] [Abstract][Full Text] [Related]
15. Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats.
Gao J; Ding X; Chu C; Lu L; Zhang Y; Chen Y; Fan W; Li G; Gao S
Eur J Pharm Sci; 2009 Mar; 36(4-5):572-9. PubMed ID: 19135531
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
[TBL] [Abstract][Full Text] [Related]
17. Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung.
Ruppert C; Kuchenbuch T; Boensch M; Schmidt S; Mathes U; Hillebrand V; Henneke I; Markart P; Reiss I; Schermuly RT; Seeger W; Günther A
Crit Care Med; 2010 Jul; 38(7):1584-91. PubMed ID: 20400897
[TBL] [Abstract][Full Text] [Related]
18. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
[TBL] [Abstract][Full Text] [Related]
19. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
Fiegel J; Fu J; Hanes J
J Control Release; 2004 May; 96(3):411-23. PubMed ID: 15120898
[TBL] [Abstract][Full Text] [Related]
20. Effervescent dry powder for respiratory drug delivery.
Ely L; Roa W; Finlay WH; Löbenberg R
Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
